SCHEMBL169519

SCHEMBL169519

Oc1cc2ncccc2c2ncccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.50
KDM4E B2RXH2 10/20 0.47
HSP90AA1 P07900 7/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
L3MBTL1 Q9Y468 5/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
IDO1 P14902 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
HTT P42858 5/20 0.47
MAPT P10636 5/20 0.47
SLC6A2 P23975 3/20 0.47
HSP90AB1 P08238 2/20 0.47
METAP2 P50579 2/20 0.47
METAP1 P53582 2/20 0.47
MPI P34949 1/20 0.47
BRD4 O60885 1/20 0.47
PSMB5 P28074 1/20 0.47
FTO Q9C0B1 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1389187 0.84 KDM4E (0.52) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL169672 0.81 LMNA (0.56) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL1408764 0.78 TRPM4 (0.55) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL15339705 0.78 PIK3CD (0.58) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL23884462 0.78 MEN1 (0.52) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL8654916 0.76 CCR1 (0.61) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL9860748 0.76 KDM4E (0.59) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL1149641 0.76 L3MBTL1 (0.61) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL1097183 0.76 HSP90AA1 (0.59) LMNAKDM4EHSP90AA1MEN1KMT2A
SCHEMBL169518 0.76 L3MBTL1 (0.61) LMNAKDM4EHSP90AA1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8652752-B2 Sulphonium salt initiators BASF SE (DE) 2014-02-18 US claimed
EP-2197840-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-11-06 EP claimed
US-20100297540-A1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2010-11-25 US claimed
EP-2197869-A1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2010-06-23 EP claimed
WO-2009047105-A1 SULPHONIUM SALT INITIATORS BASF SE (CH) 2009-04-16 WO claimed
WO-2024120467-A1 PHOSPHORAMIDATE MONOSACCHARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS SURIO THERAPEUTICS CO. LTD (CN) 2024-06-13 WO disclosed
WO-2024120442-A1 PAK4 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CONVERGEN (SUZHOU) PHARMACEUTICAL CO., LTD. (CN) 2024-06-13 WO disclosed
WO-2024120466-A1 MONOSACCARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS SURIO THERAPEUTICS CO., LTD (CN) 2024-06-13 WO disclosed
WO-2024114814-A1 JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS ONQUALITY PHARMACEUTICALS CHINA LTD (CN) 2024-06-06 WO disclosed
WO-2024104422-A1 PHOSPHORUS-CONTAINING COMPOUNDS FOR TREATING INFLAMMATORY BOWEL DIESEASE VIVAVISION BIOTECH, INC. (CN) 2024-05-23 WO disclosed
WO-2024104384-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NUCMITO PHARMACEUTICALS CO. LTD. (CN) 2024-05-23 WO disclosed
WO-2024094064-A1 PYRIMIDINYLAMINOBENZENES FOR TREATING LUNG CANCER WITH DISTANT METASTASIS SUZHOU PUHE BIOPHARMA CO., LTD (CN) 2024-05-10 WO disclosed
WO-1998041524-A1 PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON α-AMINO ALKENES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-09-24 WO disclosed
WO-1998038195-A1 PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON α-AMMONIUM KETONES, IMINIUM KETONES OR AMIDINIUM KETONES AND ARYL BORATES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-09-03 WO disclosed
EP-0857765-A2 Stabilizing agents for powder paints Ciba SC Holding AG (CH) 1998-08-12 EP disclosed
WO-1998032756-A1 SUBSTITUTED AMINOALKYLIDENAMINO TRIAZINES AS HERBICIDES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-07-30 WO disclosed
US-5773631-A PROTECTION OF POLYMERS AND LUBRICANTS AGAINST THERMAL, OXIDATIVE OR LIGHT INDUCED DEGRDATION CIBA SPECIALTY CHEMICALS CORPORATION (US) 1998-06-30 US disclosed
EP-0842975-A1 Stabilising polyolefins for long term contact with an extracting medium Ciba SC Holding AG (CH) 1998-05-20 EP disclosed
EP-0839623-A1 Stabiliser combination for rotomolding process Ciba SC Holding AG (CH) 1998-05-06 EP disclosed
US-5516920-A POLYMER STABILIZERS CIBA-GEIGY CORPORATION (US) 1996-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297540-A1 SULPHONIUM SALT INITIATORS SULT1A1, SULT2A1, NCOA1 LMNA 1159/4885KDM4E 3933/4885HSP90AA1 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.